date:Aug 13, 2014
ve rights from Dartmouth College for several patents related to pharmaceutical use of nicotinamide riboside (NR). The new licensed patents include protection for human therapeutic uses of NR and build upon the patents licensed from Dartmouth in 2012 for other human uses and production methods of NR. Mr. Jaksch commented, The acquisition of these additional Dartmouth patent rights allows for ChromaDex to commercialize NR as a drug. Together with our existing patent portfolio pertaining to NR, we